---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002688"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:57:13.223308+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027

## Summary
- Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.
- Phase 2 TibuSURE trial in SSc: topline data anticipated in first half of 2027.
- Cash and equivalents sufficient to fund operations through 2027, beyond both data readouts.
- Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways.

## SEC filing metadata
- accession: 0001104659-26-002688
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/0001104659-26-002688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/tm262894d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002688
- JSON: https://secwatch.observer/filing/0001104659-26-002688.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.